Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children

Inclusion Criteria: * Patients who completed the core study (IGE025B1301) and who in the investigator's clinical judgment could benefit from continuous treatment of the study drug. Exclusion Criteria: * Patients who currently have diagnosed cancer, are currently being investigated for possible cancer or have any history of cancer. * Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, UNLESS they are: women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner; women whose partners have been sterilized by vasectomy or other means; using a highly effective method of birth control; or agreeing on total abstinence and the investigator also judges that the age, career lifestyle or sexual orientation of the patient ensures compliance. * With clinically significant uncontrolled systemic disease (eg: infection, hematological disease, renal, hepatic, coronary heart disease or other cardiovascular disease, cerebro-vascular, endocrinologic or gastrointestinal disease) after the treatment period of the core study. * Patients with a history of major protocol violations during the core study and who are considered potentially unreliable as judged by the investigator at each site.